FDA Expands Guselkumab Label in PsA - Quiz - MDSpire

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

  • By

  • Kathryn Wighton

  • May 29, 2026

  • 2 min

Share

Original Source(s)

FDA Expands Guselkumab Label in PsA

  • by Kathryn Wighton

  • May 29, 2026

Related Content

Shoulder MRI: Rethinking Findings

Routine imaging may detect age-related tendon changes that do not explain patient-reported shoulder pain.

Medical Oddities: For the Birds—and the Brain

Birds for brains, blackout laughs, anti-aging tea, thin air, muscle memory—and torn marriages, all with a clinical touch this week.

​​​​​​​PsA Treatment Options Expand

Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.